Riders Considered in the User Fee Reauthorization
Tuesday, November 8, 2022
1:00 p.m. - 2:30 p.m.
Numerous legislative proposals were considered as part of the user-fee legislative process. Ultimately, Congress passed a clean user fee bill. This panel will discuss the future for proposed riders that were considered and not included as part of the UFA process and what industry can expect as a result.
Moderator: Margaret “Peggy” Dotzel, JD
Partner, Zuckerman Spaeder LLP
Kurt Karst, JD
Director, Hyman, Phelps & McNamara, P.C.
Brian McCormick, JD
VP, Chief Regulatory Counsel & Head, Global Regulatory Policy, Teva Pharmaceuticals
Howard Sklamberg, JD
Partner, Arnold & Porter LLP, Life Sciences and Healthcare Regulatory Practice